- Home
- PHAT vs ERII Comparison
PHAT vs ERII Comparison
Compare PHAT & ERII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- ERII
- Stock Information
- Founded
- PHAT 2018
- ERII 1992
- Country
- PHAT United States
- ERII United States
- Employees
- PHAT N/A
- ERII N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- ERII Industrial Machinery/Components
- Sector
- PHAT Health Care
- ERII Technology
- Exchange
- PHAT Nasdaq
- ERII Nasdaq
- Market Cap
- PHAT 716.5M
- ERII 754.4M
- IPO Year
- PHAT 2019
- ERII 2008
- Fundamental
- Price
- PHAT $11.91
- ERII $14.73
- Analyst Decision
- PHAT Strong Buy
- ERII Buy
- Analyst Count
- PHAT 5
- ERII 3
- Target Price
- PHAT $16.40
- ERII $18.67
- AVG Volume (30 Days)
- PHAT 1.1M
- ERII 442.7K
- Earning Date
- PHAT 08-07-2025
- ERII 08-06-2025
- Dividend Yield
- PHAT N/A
- ERII N/A
- EPS Growth
- PHAT N/A
- ERII 25.10
- EPS
- PHAT N/A
- ERII 0.43
- Revenue
- PHAT $114,039,000.00
- ERII $141,775,000.00
- Revenue This Year
- PHAT $194.40
- ERII $4.82
- Revenue Next Year
- PHAT $103.23
- ERII $12.97
- P/E Ratio
- PHAT N/A
- ERII $32.87
- Revenue Growth
- PHAT 1049.82
- ERII 6.19
- 52 Week Low
- PHAT $2.21
- ERII $10.86
- 52 Week High
- PHAT $19.71
- ERII $20.27
- Technical
- Relative Strength Index (RSI)
- PHAT 75.25
- ERII 61.64
- Support Level
- PHAT $9.82
- ERII $14.00
- Resistance Level
- PHAT $11.19
- ERII $14.55
- Average True Range (ATR)
- PHAT 0.71
- ERII 0.46
- MACD
- PHAT 0.17
- ERII 0.02
- Stochastic Oscillator
- PHAT 94.07
- ERII 72.73
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About ERII Energy Recovery Inc.
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.